|Description||Anti-PD-L1 monoclonal antibody BMS-936559 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation.|
|Brife Description||Human mAb against programmed cell death 1 ligand 1. Phase I|
|Synonyms||MDX1105; BMS936559; MDX 1105; BMS 936559; MDX-1105; BMS-936559; Anti PD L1; PD-L1 inhibitor -Bristol-Myers Squibb|
|Current Developer||Bristol-Myers Squibb|
A human immunoglobulin G1 (IgG1) monoclonal antibody binds to PD-L1 and prevents the interaction of PD-L1 with its receptor PD-1, with potential immune checkpoi...
PD-1/PD-L1 Inhibitor 1
PD-1/PD-L1 Inhibitor 1, is an inhibitor of the PD-1 /PD-Ll protein/protein interaction.
A first-in-class oral, small molecule antagonist of PD-L1, PD-L2 and V-region immunoglobulin-containing suppressor of T cell activation (VISTA).
A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibi...
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody. It was approved by FDA for the treatment of patients with locally advanced or metasta...
Avelumab is a human monoclonal antibody that is commonly used in immunotherapy and originally for non-small-cell lung carcinoma (NSCLC). It binds to the program...
MSB-2311 is a second-generation programmed cell death 1 ligand 1 (PD-L1) antibody with pH-dependent antigen binding property. The pH-dependent antigen binding p...
PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1).